MagnetisMM-5

Phase 3 Clinical Trial Evaluating The Safety and Effectiveness of Elranatamab Alone and Combined with Daratumumab Compared to the Combination of Daratumumab, Pomalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

What's the purpose of the trial?

The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclonal antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone.

Trial status

Accepting patients

Phase
Phase 3
Enrollment
944
Last Updated

Participating Centers

There are 14 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Elranatamab
  • Daratumumab
  • Dexamethasone
  • Pomalidomide

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.